drugset / Trial / NCT00784823

Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma

NCT00784823

Phase 1/2 Completed 32 enrolled Hackensack Meridian Health
Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to determine the tolerance and potential efficacy of combining dose intense melphalan with escalating doses of bortezomib in patients with multiple myeloma undergoing autologous stem cell transplantation.

Timeline

Start
2007-01
Primary completion
2013-12
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Bortezomib Small molecule 1 mg/m2 Intravenous
Subject Bortezomib Small molecule 1.3 mg/m2 Intravenous
Subject Bortezomib Small molecule 1.6 mg/m2 Intravenous
Subject Melphalan Small molecule 200 mg/m2 Intravenous

Indications